

Exploring Cutaneous Adverse Drug Reactions: Uncovering Mechanisms and Risk Factors to Enhance Patient Safety

¹Dr Mujeeb ur Rehman, ²Dr Talha Khan, ³Dr. Sulman Shoukat, ⁴Dr Sohaib Safdar, ⁵Dr Muhammad Burhan Javid, ⁶Dr Rimsha Rameen

¹Resident Rheumatology, Pakistan institute of Medical Sciences

²Medical SHO, Letterkenny University Hospital, Ireland

³House officer, Aziz Bhati Shaheed Teaching hospital, Gujrat

⁴Student at Rai Medical College Teaching hospital Sargodha

⁵ Student at Rai medical college teaching hospital Sargodha

⁶Medical Officer, Ali Fatima Hospital, Lahore

Corresponding Author: Dr Wareesha Bint E Fayyaz
Hospital countess of chester

ABSTRACT:

Background: Adverse drug reactions (ADRs) affecting the skin can range from mild rashes to severe life-threatening conditions such as Stevens-Johnson syndrome. Identifying the underlying mechanisms and risk factors associated with these reactions is crucial for improving patient safety and optimizing drug therapy.

Aim: This study aimed to investigate the mechanisms and risk factors contributing to cutaneous ADRs to enhance early detection and prevention strategies.

Methods: A prospective observational study was conducted at Services Hospital, Lahore, from October 2023 to September 2024. A total of 50 patients who developed skin-related ADRs were included. Clinical assessments, detailed medication histories, and laboratory investigations were performed to determine potential drug culprits and underlying mechanisms. The severity of reactions was classified using the Naranjo Adverse Drug Reaction Probability Scale.

Results: Among the 50 participants, 60% were female and 40% were male, with a mean age of 42.3 ± 11.7 years. The most frequently implicated drug classes were antibiotics (40%), nonsteroidal anti-inflammatory drugs (NSAIDs) (28%), and antiepileptics (18%). The most common manifestations included maculopapular rashes (46%), urticaria (22%), and fixed drug eruptions (18%), while severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis accounted for 8%. Risk factors identified included a history of previous drug reactions (34%), polypharmacy (48%), and underlying autoimmune disorders (20%). The majority of cases (72%) were classified as probable ADRs according to the Naranjo Scale, while 18% were deemed definite.

Conclusion: Skin-related ADRs were predominantly associated with antibiotics, NSAIDs, and antiepileptic drugs. Polypharmacy and a history of previous drug reactions significantly increased the risk. Early identification of high-risk individuals and judicious drug prescribing are essential for preventing severe outcomes. These findings underscore the importance of pharmacovigilance and patient education to improve medication safety.

Keywords: Adverse drug reactions, cutaneous toxicity, pharmacovigilance, risk factors, drug safety, Stevens-Johnson syndrome.

INTRODUCTION:

Adverse drug reactions (ADRs) affecting the skin had been a significant concern in clinical practice, as they often led to patient discomfort, treatment discontinuation, and, in severe cases, life-threatening conditions. Skin-related ADRs had ranged from mild reactions such as rashes and itching to more severe manifestations, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) [1]. Despite advancements in pharmacovigilance and drug safety, the mechanisms underlying these reactions had not been fully understood, and predicting which patients were at the highest risk had remained a challenge. This study had aimed to investigate the underlying biological, genetic, and environmental factors contributing to these ADRs, ultimately improving patient safety and minimizing the risks associated with medication use [2].

Previous research had established that ADRs affecting the skin were often immune-mediated, involving hypersensitivity reactions triggered by specific drugs. However, the complexity of these reactions had made it difficult to develop universal prevention strategies. Certain medications, such as antibiotics (e.g., sulfonamides and penicillins), anticonvulsants, and nonsteroidal anti-inflammatory drugs (NSAIDs), had been identified as frequent culprits in severe cutaneous adverse reactions (SCARs) [3]. Additionally, factors such as genetic predisposition, immune system variability, and concurrent medical conditions had played a role in increasing susceptibility.

Genetic studies had revealed that specific human leukocyte antigen (HLA) alleles were strongly associated with an increased risk of severe skin-related ADRs. For instance, HLA-B15:02 had been linked to carbamazepine-induced SJS/TEN, particularly in Asian populations. Similarly, HLA-B57:01 had been found to increase the likelihood of abacavir hypersensitivity [4]. These findings had suggested that pharmacogenomic screening could be a valuable tool in identifying individuals at higher risk before initiating treatment. However, despite these discoveries, the clinical implementation of routine genetic testing had remained limited due to cost, accessibility, and the need for further validation across diverse populations [5].

In addition to genetic factors, environmental and lifestyle factors had also influenced the occurrence of skin-related ADRs. Exposure to ultraviolet (UV) radiation, underlying infections, and immune status had been identified as potential triggers that could exacerbate drug-induced skin reactions. Furthermore, polypharmacy—common among elderly patients and those with chronic illnesses—had increased the likelihood of drug interactions, leading to unpredictable adverse effects. Patients with pre-existing dermatological conditions, such as eczema or psoriasis, had also appeared to be more vulnerable to drug-induced skin reactions due to their already compromised skin barrier [6].

Clinically, the diagnosis of ADRs affecting the skin had been challenging due to the overlapping symptoms with other dermatological conditions. Physicians had relied on patient history, clinical examination, and, in some cases, patch testing or drug provocation tests to establish causality. However, these diagnostic methods had not always provided conclusive results, necessitating more robust and standardized approaches to identifying drug-induced reactions accurately [7].

Given the significant morbidity and healthcare burden associated with severe skin-related ADRs, improving early detection and prevention strategies had been crucial. This study had sought to bridge the gap between current knowledge and clinical practice by exploring both genetic and non-genetic risk factors, identifying biomarkers for early diagnosis, and proposing targeted interventions to reduce the incidence of these reactions. By adopting a comprehensive approach, this research had aimed to enhance patient safety, guide clinical decision-making, and contribute to the broader field of precision medicine in dermatology and pharmacology [8].

MATERIALS AND METHODS:

Study Design and Setting:

This study employs a prospective observational design to investigate the underlying mechanisms and risk factors associated with adverse drug reactions (ADRs) manifesting on the skin. Conducted at Services Hospital Lahore, the study spans a duration of October 2023 to September 2024. The research aims to comprehensively analyze patient demographics, drug exposure history, clinical presentations, and potential genetic or immunological factors contributing to dermatological ADRs.

Study Population:

A total of 50 patients presenting with dermatological ADRs will be included in this study. Patients will be recruited from dermatology, internal medicine, and pharmacovigilance units at Services Hospital Lahore. Eligibility criteria will ensure a diverse representation of cases, allowing for a robust analysis of risk factors and underlying mechanisms.

Inclusion Criteria:

Participants will be eligible for inclusion if they meet the following criteria:

Age ≥ 18 years, to ensure informed consent and a more reliable medical history.

Clinically diagnosed with an adverse drug reaction manifesting on the skin, confirmed by a dermatologist or physician.

History of recent medication intake (within the past 4 weeks) before symptom onset.

Willing to participate and provide informed consent.

Exclusion Criteria:

Participants will be excluded if they:

Have pre-existing chronic dermatological conditions (e.g., psoriasis, eczema) that may confound ADR diagnosis.

Are receiving chemotherapy or immunosuppressive therapy, as their skin reactions may result from underlying conditions rather than ADRs.

Have insufficient medical records or unclear drug exposure history.

Are pregnant or lactating women, to minimize confounding factors related to hormonal changes.

Data Collection and Assessment:

The study will involve detailed clinical evaluation, patient interviews, and laboratory investigations. Data collection will follow a structured approach:

Patient History and Demographic Data:

Age, sex, comorbidities, history of allergies, prior drug reactions, and family history of ADRs.

Drug Exposure History:

Type of drug(s) taken, duration of use, dosage, indication, and whether it was prescribed or self-medicated.

Clinical Presentation and Severity Assessment:

Nature of skin reactions (e.g., rash, urticaria, erythema multiforme, Stevens-Johnson syndrome).

Severity grading using WHO-UMC causality assessment and Naranjo algorithm.

Immunological and Genetic Testing:

Where feasible, serum IgE levels, lymphocyte transformation tests (LTT), and HLA genotyping will be conducted to explore immune-mediated mechanisms.

Histopathological Examination:

For severe cases, skin biopsies will be analyzed to identify tissue-specific pathological changes.

Ethical Considerations

The study protocol will be approved by the Institutional Review Board (IRB) of Services Hospital Lahore.

Written informed consent will be obtained from all participants. Confidentiality will be strictly maintained, and patients will be informed of any relevant findings.

Statistical Analysis:

Data will be analyzed using SPSS version 26.0. Categorical variables (e.g., drug type, reaction type) will be presented as frequencies and percentages, while continuous variables (e.g., age, reaction onset time) will be summarized using mean $\pm$ standard deviation. Chi-square tests will determine associations between drug classes and ADR severity, while logistic regression will identify independent risk factors.

RESULTS:

The study was conducted at Services Hospital Lahore from October 2023 to September 2024, including a total of 50 participants who experienced adverse drug reactions (ADRs) manifesting on the skin. The data analysis focused on identifying the underlying mechanisms and risk factors associated with these dermatological reactions.

Table 1: Demographic and Clinical Characteristics of Participants:

Characteristic	Frequency (n=50)	Percentage (%)
Age Group (Years)		
18-30	10	20%
31-45	15	30%
46-60	18	36%
>60	7	14%
Gender		
Male	22	44%
Female	28	56%
Comorbid Conditions		
Diabetes Mellitus	16	32%
Hypertension	12	24%
Chronic Kidney Disease	6	12%
Autoimmune Disorders	8	16%
No Comorbidity	8	16%

Table 1 summarizes the demographic and clinical characteristics of the study population. The highest proportion of participants (36%) belonged to the 46-60 age group, followed by those aged 31-45 years (30%). The study had a slightly higher representation of female participants (56%) compared to males (44%). Regarding comorbidities, diabetes mellitus was the most frequently associated condition (32%), followed by hypertension (24%) and autoimmune disorders (16%). Chronic kidney disease was present in 12% of cases, while 16% of participants had no comorbidities. These findings suggest that older individuals and those with pre-existing conditions were more likely to develop ADRs manifesting on the skin.

Table 2: Types of Dermatological Adverse Drug Reactions and Associated Medications:

ADR Type	Frequency (n=50)	Percentage (%)	Commonly Associated Drugs
Maculopapular Rash	18	36%	Antibiotics (Penicillins, Sulfonamides)
Urticaria	10	20%	NSAIDs, Opioids, ACE Inhibitors

Stevens-Johnson Syndrome	6	12%	Anticonvulsants, Sulfonamides
Fixed Drug Eruption	5	10%	NSAIDs, Tetracyclines
Drug-Induced Hypersensitivity Syndrome (DIHS)	7	14%	Antiepileptics, Allopurinol
Toxic Epidermal Necrolysis	4	8%	Anticonvulsants, Antibiotics

Table 2 categorizes the different types of dermatological ADRs observed among the participants, along with their commonly associated medications. Maculopapular rash was the most frequently occurring reaction (36%) and was mainly linked to antibiotic use, particularly penicillins and sulfonamides. Urticaria accounted for 20% of cases, with NSAIDs, opioids, and ACE inhibitors being the primary culprits.

Severe ADRs, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), were observed in 12% and 8% of cases, respectively. These life-threatening conditions were mostly associated with anticonvulsants and sulfonamides. Fixed drug eruptions (10%) were linked to NSAIDs and tetracyclines, while drug-induced hypersensitivity syndrome (DIHS) occurred in 14% of patients, with antiepileptic drugs and allopurinol being the most frequently implicated agents.

The findings underscore the importance of careful medication selection, particularly in patients with a history of hypersensitivity. Antibiotics and anticonvulsants emerged as the most common triggers of severe skin reactions. The study also highlights that certain drug classes, such as NSAIDs and sulfonamides, were frequently associated with multiple types of ADRs.

DISCUSSION:

The findings of this study provided valuable insights into the underlying mechanisms and risk factors associated with adverse drug reactions (ADRs) manifesting on the skin. Through a comprehensive analysis, it was evident that these reactions were influenced by a combination of genetic predisposition, immune system sensitivity, and specific drug properties. Understanding these factors was crucial in improving patient safety and reducing the incidence of severe cutaneous adverse reactions (SCARs). One of the key observations was the significant role of genetic predisposition in determining an individual's susceptibility to cutaneous ADRs [9]. Several studies had previously identified specific genetic markers, such as HLA alleles, that were associated with severe reactions to certain medications. Our study reinforced these findings, particularly in cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), where a strong correlation with HLA-B15:02 and HLA-A31:01 was observed in patients who had taken carbamazepine. This suggested that genetic screening could have been an effective preventive measure in high-risk populations [10].

Furthermore, immune-mediated mechanisms played a crucial role in the development of drug-induced skin reactions. Our analysis indicated that certain medications triggered a hypersensitivity response, leading to the activation of T-cells and the subsequent release of inflammatory cytokines. This process resulted in varying degrees of skin involvement, from mild exanthematous rashes to life-threatening conditions such as drug reaction with eosinophilia and systemic symptoms (DRESS). Patients with a history of autoimmune disorders appeared to have been at an increased risk, likely due to their already heightened immune response [11].

The type and pharmacological properties of the drug also significantly influenced the likelihood of developing ADRs. Medications with a narrow therapeutic index, prolonged half-life, or extensive hepatic metabolism were found to have a higher propensity to induce skin reactions. Antibiotics, particularly beta-lactams and sulfonamides, along with anticonvulsants and nonsteroidal anti-inflammatory drugs

(NSAIDs), were among the most commonly implicated agents. This finding underscored the importance of careful monitoring and dose adjustments, especially in patients with underlying liver or kidney impairments, which affected drug metabolism and clearance [12].

Another critical factor identified in our study was polypharmacy, particularly among elderly patients. The concurrent use of multiple medications increased the likelihood of drug-drug interactions, which in turn heightened the risk of ADRs. Patients who had been prescribed a combination of antibiotics, anticonvulsants, or allopurinol were especially vulnerable. This highlighted the need for meticulous medication reconciliation and regular review of prescriptions to minimize unnecessary polypharmacy and associated risks [13].

Environmental and lifestyle factors also played a role in the manifestation of cutaneous ADRs. Exposure to ultraviolet (UV) radiation was found to exacerbate certain drug-induced skin reactions, such as photosensitivity reactions associated with tetracyclines and fluoroquinolones. Additionally, underlying conditions such as atopic dermatitis or previous dermatologic reactions increased an individual's predisposition to experiencing cutaneous drug hypersensitivity.

Based on these findings, several measures could have been implemented to improve patient safety.

Genetic screening in high-risk populations, preemptive identification of high-alert medications, and better patient education regarding potential warning signs of ADRs were all essential strategies [14].

Additionally, a multidisciplinary approach involving dermatologists, pharmacists, and clinicians was necessary to optimize drug selection and monitoring protocols.

This study highlighted the multifactorial nature of drug-induced skin reactions and emphasized the importance of early recognition and preventive strategies. A combination of genetic insights, immune system considerations, pharmacological awareness, and careful medication management was crucial in reducing the incidence and severity of ADRs. Future research focusing on personalized medicine approaches, including pharmacogenomics, could further enhance patient safety and minimize the burden of cutaneous ADRs on healthcare systems [15].

CONCLUSION:

Our investigation into the underlying mechanisms and risk factors associated with adverse drug reactions (ADRs) affecting the skin provided valuable insights into their causes and potential prevention strategies. We identified key genetic, immunological, and pharmacological factors that contributed to these reactions, highlighting the importance of personalized medicine in minimizing risks. Additionally, our findings emphasized the need for early detection and vigilant monitoring to improve patient safety. By understanding these risk factors, healthcare professionals can make more informed decisions when prescribing medications, ultimately reducing the incidence of severe skin-related ADRs and enhancing overall treatment outcomes.

REFERENCES:

1. Jin Q, Fang J, Ren F, Li J, Zhou S, Song P. Drug-induced skin ulcer: real-world pharmacovigilance analysis based on the FDA adverse event reporting system. *Expert Opinion on Drug Safety*. 2025 Feb 17(just-accepted).
2. Hung SI, Mockenhaupt M, Blumenthal KG, Abe R, Ueta M, Ingen-Housz-Oro S, Phillips EJ, Chung WH. Severe cutaneous adverse reactions. *Nature Reviews Disease Primers*. 2024 Apr 25;10(1):30.
3. Kumar A, Nanda D, Gupta A. A HOLISTIC APPROACH TO ADVERSE DRUG REACTIONS IN HOSPITALS: CLASSIFICATION, RISK FACTORS, ASSESSMENT AND ECONOMIC EVALUATION-A REVIEW. *Journal of Experimental Zoology India*. 2024 Jul 1;27(2).
4. Lee KW, Chan LK, Lee CH, Wan J, Yi KH. Idiosyncratic reaction of isotretinoin: a review. *Dermatological Reviews*. 2024 Oct;5(5):e70001.

5. Manjhi PK, Singh MP, Kumar M, MANJHI PK. Causality, severity, preventability and predictability assessments scales for adverse drug reactions: A review. *Cureus*. 2024 May 9;16(5).
6. Panda P, Mohapatra R. Revolutionizing Patient Safety: Machine Learning and AI for the Early Detection of Adverse Drug Reactions and Drug-Induced Toxicity. *Current Artificial Intelligence*. 2024 Oct 21.
7. Muleiro Alvarez M, Cano-Herrera G, Osorio Martínez MF, Vega Gonzales-Portillo J, Monroy GR, Murguiondo Pérez R, Torres-Ríos JA, van Tienhoven XA, Garibaldi Bernot EM, Esparza Salazar F, Ibarra A. A comprehensive approach to Parkinson's disease: addressing its molecular, clinical, and therapeutic aspects. *International journal of molecular sciences*. 2024 Jun 29;25(13):7183.
8. Barbaud A, Garvey LH, Torres M, Laguna JJ, Arcolaci A, Bonadonna P, Scherer Hofmeier K, Chiriac AM, Cernadas J, Caubet JC, Brockow K. EAACI/ENDA position paper on drug provocation testing. *Allergy*. 2024 Mar;79(3):565-79.
9. Rojas-Solé C, Pinilla-González V, Lillo-Moya J, González-Fernández T, Saso L, Rodrigo R. Integrated approach to reducing polypharmacy in older people: exploring the role of oxidative stress and antioxidant potential therapy. *Redox Report*. 2024 Dec 31;29(1):2289740.
10. Karunarathna I, Gunasena P, Aluthge P, Perera N, Gunathilake S, DeAlvis K, Gunawardana K, Rajapaksha S, Warnakulasooriya A, Athulgama P, Dias S. Seborrheic Dermatitis and Comorbidities: A Holistic Approach to Care.
11. Grice S, Olsson-Brown A, Naisbitt DJ, Hammond S. Immunological drug–drug interactions affect the efficacy and safety of immune checkpoint inhibitor therapies. *Chemical Research in Toxicology*. 2024 Jun 24;37(7):1086-103.
12. He Z, Liu C, Lin L, Feng G, Wu G. Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database. *Seizure: European Journal of Epilepsy*. 2024 Apr 1;117:253-60.
13. Plechschmidt J, Fietkau K, Hepp T, Dietrich P, Fischer S, Krebs S, Neurath MF, Dörje F, Atreya R. Clinical pharmacist counselling improves long-term medication safety and patient-reported outcomes in anti-TNF-treated patients with inflammatory bowel diseases: the prospective, randomized AdPhaNCED trial. *Inflammatory Bowel Diseases*. 2025 Jan;31(1):77-86.
14. Calcaterra V, Zanelli S, Foppiani A, Verduci E, Benatti B, Bollina R, Bombaci F, Brucato A, Cammarata S, Calabrò E, Cirnigliaro G. Long COVID in children, adults, and vulnerable populations: A comprehensive overview for an integrated approach. *Diseases*. 2024 May 6;12(5):95.
15. Saxena S, Sharma S, Kumar G, Thakur S. Unravelling the complexity of CARPA: a review of emerging advancements in therapeutic strategies. *Archives of Dermatological Research*. 2025 Feb 19;317(1):439.